NCI Deputy Director’s Update
James H. Doroshow, M.D.

July 11, 2018
NCI Appropriations FY 2014-2019 (in millions)

Source: NCI Office of Budget and Finance
### FY 2018 NCI Budget Overview
(dollars in thousands)

<table>
<thead>
<tr>
<th>Appropriation Increase over FY 2017(^1)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>FY 2017 Enacted</td>
<td>$5,389,329</td>
</tr>
<tr>
<td>FY 2018 Enacted</td>
<td>$5,664,800</td>
</tr>
<tr>
<td><strong>Appropriation Increase</strong></td>
<td><strong>$275,471</strong></td>
</tr>
</tbody>
</table>

\(^1\) Does not include $300M 21st Century Cures funding for Cancer Moonshot

<table>
<thead>
<tr>
<th>Estimated Increase, as of 6/22/2018</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Taps, Assessments, Transfers, Salaries &amp; Benefits</td>
<td>$37,900</td>
</tr>
<tr>
<td>Small Business Set Aside</td>
<td>$10,000</td>
</tr>
<tr>
<td>Additional Investments in the RPG Pool</td>
<td>$147,000</td>
</tr>
<tr>
<td>Centers and SPOREs</td>
<td>$20,000</td>
</tr>
<tr>
<td>Targeted Research Opportunities</td>
<td>$50,571</td>
</tr>
<tr>
<td>NCTN and NCORP</td>
<td>$10,000</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$275,471</strong></td>
</tr>
</tbody>
</table>
## FY 2018 NCI Budget Overview

### Targeted Research Opportunities

<table>
<thead>
<tr>
<th>Opportunity</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genomic Profiling of Lung Cancer in Never Smokers in General &amp; Special Populations</td>
<td></td>
</tr>
<tr>
<td><strong>The Cancer Imaging Archive</strong></td>
<td></td>
</tr>
<tr>
<td>Data Integration and Analysis for APOLLO</td>
<td></td>
</tr>
<tr>
<td><strong>Glioblastoma Research Pilot Project</strong></td>
<td></td>
</tr>
<tr>
<td>New Onset Diabetes (NOD) Cohort Biorepository</td>
<td></td>
</tr>
<tr>
<td>Cancer Research Education Grants to Promote Diversity (R25’s)</td>
<td></td>
</tr>
</tbody>
</table>

1. *This table does not represent the entire population of Targeted Research Opportunities in FY 2018, but rather a select few*
NATIONAL TRENDS IN CANCER DEATH RATES

MEN
- Non-Melanoma Skin
- Liver & Intrabiliary Bile Duct
- Oral Cavity & Pharynx
- Soft Tissue incl. Heart
- Brain & Other Nervous System
- Pancreas
- Kidney & Renal Pelvis
- Bladder
- Myeloma
- Esophagus
- Stomach
- All Sites
- Non-Hodgkin Lymphoma
- Prostate
- Leukemia
- Colon & Rectum
- Larynx
- Melanoma of the Skin
- Lung & Bronchus

WOMEN
- Liver & Intrabiliary Bile Duct
- Corpus & Uterus
- Brain & Other Nervous System
- Pancreas
- Soft Tissue incl. Heart
- Myeloma
- Bladder
- Cervix
- Oral Cavity & Pharynx
- Gallbladder
- Kidney & Renal Pelvis
- All Sites
- Breast
- Esophagus
- Stomach
- Ovary
- Leukemia
- Lung & Bronchus
- Melanoma of the Skin
- Colon & Rectum
- Non-Hodgkin Lymphoma

AVERAGE ANNUAL PERCENT CHANGE (AAPC) 2011-2015

1999 — 2015 CANCER DEATH RATES DECLINED FOR MEN, WOMEN, & CHILDREN
## Recently Approved Concepts

<table>
<thead>
<tr>
<th>CONCEPT</th>
<th>DOC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Implementation Science Centers for Cancer Control</td>
<td>DCCPS</td>
</tr>
<tr>
<td>Communication and Decision Making in the Context of Risk and Uncertainty for Individuals with Inherited Cancer Syndromes</td>
<td>DCCPS</td>
</tr>
<tr>
<td>Moonshot New RFAs - Immuno-Oncology Translational Network</td>
<td>DCB</td>
</tr>
<tr>
<td>NCI Awardee Skills Development Consortium (NASDC)</td>
<td>OD-CCT</td>
</tr>
<tr>
<td>Pathway to Independence Award for Outstanding Early-Stage Postdoctoral Fellows (RFA: K88/R00)</td>
<td>OD-CCT</td>
</tr>
<tr>
<td>U.S.-China Program for Biomedical Collaborative Research</td>
<td>OD-CGCHR, DCCPS, DCP, DCTD</td>
</tr>
<tr>
<td>The Experimental Therapeutics Clinical Trials Network (previous title Early Clinical Trials of New Anticancer Agents With Phase 1 and 2 Emphasis)</td>
<td>DCTD</td>
</tr>
</tbody>
</table>
Key Focus Areas

**BASIC SCIENCE**
Reaffirm our commitment to basic science to drive novel approaches and technologies

**WORKFORCE DEVELOPMENT**
Support the cancer research enterprise by focusing on the workforce of cancer investigators

**BIG DATA**
Increase data aggregation and interpretation to speed our work across the cancer enterprise

**CLINICAL TRIALS**
Fully realize the power of clinical trials through innovative design, administration, and analyses
Basic Science:
Frederick National Lab Updates

RAS

CryoEM

Frederick Cell Facility
Key Focus Areas

**BASIC SCIENCE**
Reaffirm our commitment to basic science to drive novel approaches and technologies

**WORKFORCE DEVELOPMENT**
Support the cancer research enterprise by focusing on the workforce of cancer investigators

**BIG DATA**
Increase data aggregation and interpretation to speed our work across the cancer enterprise

**CLINICAL TRIALS**
Fully realize the power of clinical trials through innovative design, administration, and analyses
NCI recognizes that Early Stage Investigators (ESI) face challenges.

In addition to increased ESI payline, NCI is announcing its new use of the MERIT Award in 2018.

The award gives eligible investigators applying for first R01 the opportunity to obtain up to seven years of grant funding (5+2).

This will provide critical time for ESIs to launch their careers and become more established before attempting renewal.
Key Focus Areas

**BASIC SCIENCE**
Reaffirm our commitment to basic science to drive novel approaches and technologies

**WORKFORCE DEVELOPMENT**
Support the cancer research enterprise by focusing on the workforce of cancer investigators

**BIG DATA**
Increase data aggregation and interpretation to speed our work across the cancer enterprise

**CLINICAL TRIALS**
Fully realize the power of clinical trials through innovative design, administration, and analyses
Big Data: Data Infrastructure Investments

• Cancer Cloud Resources
• Data Commons Framework Services
• New reporting tools for better insight into active clinical trials
• Recommitment to DOE collaboration*
• Prototype CRDC nodes for imaging and proteomics*
• Collaborations that enable integration of EHR and insurance claims data with SEER*

*Supported by funds authorized by the 21st Century CURES Act.
Key Focus Areas

**BASIC SCIENCE**
Reaffirm our commitment to basic science to drive novel approaches and technologies

**WORKFORCE DEVELOPMENT**
Support the cancer research enterprise by focusing on the workforce of cancer investigators

**BIG DATA**
Increase data aggregation and interpretation to speed our work across the cancer enterprise

**CLINICAL TRIALS**
Fully realize the power of clinical trials through innovative design, administration, and analyses
Clinical Trials

MATCH

LungMAP

ALCHEMIST

Trial Metrics: S1400

<table>
<thead>
<tr>
<th>Metric</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total sites open for S1400</td>
<td>628</td>
</tr>
<tr>
<td>Total pts registered to S1400</td>
<td>1672</td>
</tr>
<tr>
<td>Total pts registered to S1400A</td>
<td>116</td>
</tr>
<tr>
<td>Total pts registered to S1400B</td>
<td>39</td>
</tr>
<tr>
<td>Total pts registered to S1400C</td>
<td>53</td>
</tr>
<tr>
<td>Total pts registered to S1400D</td>
<td>3</td>
</tr>
<tr>
<td>Total pts registered to S1400E</td>
<td>485</td>
</tr>
<tr>
<td>Total pts registered to S1400I</td>
<td>275</td>
</tr>
</tbody>
</table>

NCI-MPACT

Pediatric MATCH
**Trial Assigning Individualized Options for Treatment (TAILORx)**

- **21-gene recurrence-score assay** (Oncotype DX, Genomic Health) predicts breast cancer recurrence

- Women with early-stage, HR-positive, HER2-negative, axillary lymph node-negative breast cancer and **INTERMEDIATE score** were randomly assigned to receive hormone therapy alone or hormone therapy with adjuvant chemotherapy

- **No benefit from receiving chemotherapy** plus hormone therapy versus hormone therapy only for most intermediate-risk women (except some < 50 years old)

“Results from TAILORx give clinicians high-quality data to inform personalized treatment recommendations for women”

- Joseph A. Sparano, MD
NAVIGATE will make it easier for veterans to access state-of-the-art treatments via clinical trials by bringing NCI trials to them, rather than seeking treatment outside of the Veterans Health Administration.
NAVIGATE Goals

• Enable more VA patients to enroll in NCI national clinical trials

• Provide infrastructure funding support to 12 VA sites for enrollment of VA patients to NCTN and NCORP clinical trials

• Facilitate policy, operational, or other changes to promote conduct of cancer clinical trials at VA

• Longer term goals include seeking ways to sustain VA participation in NCI clinical trials
<table>
<thead>
<tr>
<th>LOCATION</th>
<th>PI(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atlanta, GA</td>
<td>Wayne Harris, MD</td>
</tr>
<tr>
<td>Bronx, NY / James J. Peters VAMC</td>
<td>Susan Bates, MD</td>
</tr>
<tr>
<td>Charleston, SC / Ralph H. Johnson VAMC</td>
<td>Rinah Shopnik DO, Stephen Savage, MD</td>
</tr>
<tr>
<td>Denver, CO</td>
<td>Daniel Bowles, MD</td>
</tr>
<tr>
<td>Durham, NC</td>
<td>Daphne Friedman, MD</td>
</tr>
<tr>
<td>Edward Hines Jr (IL) VAMC</td>
<td>Cheryl Czerlanis, MD</td>
</tr>
<tr>
<td>Long Beach (CA) / Tibor Rubin VAMC</td>
<td>Viola Zhu, MD, PhD</td>
</tr>
<tr>
<td>Minneapolis, MN</td>
<td>Sharon Luikart, MD, Mark Klein, MD</td>
</tr>
<tr>
<td>Palo Alto, CA</td>
<td>Harlan Pinto, MD</td>
</tr>
<tr>
<td>Portland, OR</td>
<td>Mark Garzotto, MD</td>
</tr>
<tr>
<td>San Antonio, TX</td>
<td>Michael Liss, MD, Paromita Datta, MD</td>
</tr>
<tr>
<td>West Haven, CT</td>
<td>Herta Chao, MD, PhD</td>
</tr>
<tr>
<td>Boston, MA (Coordinating Center)</td>
<td>Mary Brophy, MD, MPH</td>
</tr>
</tbody>
</table>
2018
Cancer Clinical Investigator Team Leadership Recipients
Cancer Clinical Investigator Team Leadership Award

Purpose:

• Recognize and support outstanding clinical investigators at NCI-designated Cancer Centers who are actively engaged in NCI-funded collaborative clinical trials.

• Promote the retention of clinical investigators in academic clinical research careers.
Cancer Clinical Investigator Team Leadership Award

- 10 to 13 new awards per year
- $60,000 per year for 2 years
- 15% effort; time protected by sponsoring institution
- Candidate nominated by NCI Cancer Center Director
- First awards made in 2009; 114 recipients to date
- 93% (53/57) remain at NCI-Designated Cancer Center 5 years after award
Cancer Clinical Investigator Team Leadership Award

Supported activities include:

• Engaging fellows and new faculty in collaborative clinical research efforts
• Mentoring
• Organizing courses, lecture/seminar series, educational sessions, or workshops related to clinical trials
• Participating on cancer center committees related to clinical trials
• Developing a clinical trial
• Designing and implementing initiatives to better coordinate, support and integrate clinical trials efforts at the institution
Cancer Clinical Investigator Team Leadership Award

Eligibility:

• Engaged in conducting NCI-funded cancer clinical trials
• Practicing at least 3 years but no more than 8 years post-fellowship
• Currently practicing in the oncology clinical setting; board certified
• Full-time faculty member, assistant or associate professor level
• Physician or oncology nurse, clinical psychologist, or similarly qualified clinician with a doctoral degree
2018 Award Recipients
2018 CCITLA Recipients

Amy DeZern, MD, MHS
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Focus: Myelodysplastic syndromes, aplastic anemia, leukemia

Ryan Gentzler, MD, MS
UVA Cancer Center, University of Virginia
Focus: Thoracic oncology, immunotherapy
2018 CCITLA Recipients

Ahmad Halwani, MD
Huntsman Cancer Institute, University of Utah
Focus: Immune therapy in lymphoid malignancies, real world practices & outcomes using electronic health records information

Caron Jacobson, MD, MMS
Dana-Farber/Harvard Cancer Center
Focus: Lymphoma, immunotherapy
2018 CCITLA Recipients

Michael Liss, MD, MAS
Cancer Therapy & Research Center
University of Texas Health Science Center at San Antonio
Focus: Genitourinary cancers

Jason Luke, MD
University of Chicago Comprehensive Cancer Center
Focus: Melanoma, advanced solid tumors, immunotherapy
2018 CCITLA Recipients

Aaron Mansfield, MD
Mayo Clinic Cancer Center
Focus: Thoracic oncology, early phase trials, drug development

Jonathan Riess, MD, MS
UC Davis Comprehensive Cancer Center
Focus: Lung cancer, immunotherapy
2018 CCITLA Recipients

Solmaz Sahebjam, MD
Moffitt Cancer Center
Focus: Neuro-oncology, early phase trials, drug development

Robert Wesolowski, MD
The Ohio State University Comprehensive Cancer Center
Focus: Breast cancer, early phase trials in patients with solid tumors, drug development
Karen Winkfield, MD, PhD
Wake Forest Baptist Comprehensive Cancer Center
Focus: Radiation therapy for the treatment of hematologic malignancies, health disparities

Amer Zeidan, MBBS, MHS
Yale Cancer Center
Focus: Myelodysplastic syndrome, acute myeloid leukemia, immunotherapy, effectiveness and outcomes research in hematologic malignancies
Congratulations!

Cancer Clinical Investigator Team Leadership Awardees
Thank You!

Reviewers

CCCT Program Staff
Jennifer Hayes
Sarah Fabian
cancer.gov

cancer.gov/espanol